Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 10/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890867 | 0.88 | CALML3 (0.40) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL2890506 | 0.87 | CALML3 (0.42) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL5223015 | 0.87 | CALML3 (0.42) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL5223052 | 0.86 | CALML3 (0.38) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL2890869 | 0.83 | MAOA (0.43) | CALML3CYP2C19MAOAMAOBCYP3A4 | |
| SCHEMBL2896788 | 0.83 | F10 (0.40) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL2890769 | 0.83 | MAOA (0.44) | CALML3MAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL2896721 | 0.83 | CALML3 (0.41) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL5223060 | 0.82 | CALML3 (0.38) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL2896279 | 0.82 | MAOA (0.51) | CALML3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | CALML3 3047/4885CYP2C19 273/4885CYP2C9 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.